Showing 2231-2240 of 5909 results for "".
- Contact Lens Institute Extends Partnership with Actress Kate Flannery for The EASY Way Campaignhttps://modernod.com/news/contact-lens-institute-extends-partnership-with-actress-kate-flannery-for-the-easy-way-campaign/2484132/The Contact Lens Institute (CLI) announced the continuation of its partnership with actress and comedian Kate Flannery to promote 'The EASY Way,' an initiative that aims to help eye care professionals encourage healthy contact lens wear-and-care b
- Nanoscope Secures EMA Orphan Designations and FDA RMAT Status for Retinal Gene Therapy MCO-010https://modernod.com/news/nanoscope-secures-ema-orphan-designations-and-fda-rmat-status-for-retinal-gene-therapy-mco-010/2484130/Nanoscope Therapeutics announced regulatory milestones in both Europe and the United States for its lead gene therapy candidate, MCO-010 (sonpiretigene isteparvovec). The European Medicines Agency (EMA) has granted Orphan D
- FDA Grants Fast Track Designation to Aldeyra’s ADX-2191 for Retinitis Pigmentosahttps://modernod.com/news/fda-grants-fast-track-designation-to-aldeyras-adx-2191-for-retinitis-pigmentosa/2484124/The FDA has granted Fast Track Designation for Aldeyra Therapeutics' ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa (RP). The FDA’s Fast Track progra
- AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Diseasehttps://modernod.com/news/aavantgarde-bio-announces-fda-fast-track-designation-for-aavb-039-for-the-treatment-of-stargardt-disease/2484122/AAVantgarde Bio announced that the US FDA has granted Fast Track Designation for AAVB-039, the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4. The Investigational New Drug application for AAVB-039 was cleared to proceed by the FDA. St
- Nordic Pharma’s Lacrifill Canalicular Gel Highlighted in DEWS III Reporthttps://modernod.com/news/nordic-pharmas-lacrifill-canalicular-gel-highlighted-in-landmark-dews-iii-report/2482927/Nordic Pharma, a subsidiary of Nordic Group BV, announced that its Lacrifill Canalicular Gel—a novel therapy for the relief of dry eye symptoms—has been featured in the newly released Dry Eye Workshop (DEWS) III report from the Tear Film and O
- Kate Flannery Teams Up with Contact Lens Institute to Promote 'The EASY Way' for Contact Lens Healthhttps://modernod.com/news/kate-flannery-teams-up-with-contact-lens-institute-to-promote-the-easy-way-for-contact-lens-health/2482914/Comedian Kate Flannery has partnered with the Contact Lens Institute (CLI) to amplify a new campaign titled 'The EASY Way,' with the goal of communicating safe, effective soft contact lens wear-and-care routines.
- Vision Advocates Rally to Defend National Eye Institute from Funding Cuts and Consolidation Threatshttps://modernod.com/news/vision-advocates-rally-to-defend-national-eye-institute-from-funding-cuts-and-consolidation-threats/2482913/Vision science and eye care organizations are mobilizing efforts to combat proposals circulating in Washington to slash federal vision funding and consolidate the National Eye Institute (NEI) into a broader institute on brain and dental research.
- Lenz Therapeutics Receives FDA Approval of VIZZ for the Treatment of Presbyopiahttps://modernod.com/news/lenz-therapeutics-receives-fda-approval-of-vizz-for-the-treatment-of-presbyopia/2482912/A new, first-of-its kind presbyopia drop will soon be available in the US as the FDA approved Lenz Therapeutics' VIZZ (aceclidine ophthalmic solution) 1.44%. Expected to be broadly available in the fourth quarter of 2025, VIZZ is the first and only FDA-approved aceclidine-based
- Viridian Therapeutics Enters Collaboration to Develop and Commercialize Thyroid Eye Disease Therapies in Japanhttps://modernod.com/news/viridian-therapeutics-enters-collaboration-to-develop-and-commercialize-thyroid-eye-disease-therapies-in-japan/2482910/Viridian Therapeutics announced an exclusive collaboration and license agreement with Kissei Pharmaceutical to develop and commercialize investigatonal drug candidates veligrotug and VRDN-003 in Japan. Both veligrotug and
- Boehringer Ingelheim and Re-Vana Therapeutics Collaborate to Develop Long-Acting Ophthalmic Therapieshttps://modernod.com/news/boehringer-ingelheim-and-re-vana-therapeutics-announce-collaboration-to-develop-long-acting-ophthalmic-therapies/2482905/Boehringer Ingelheim and Re-Vana Therapeutics announced a strategic collaboration and license agreement designed to accelerate the development of first-in-class extended-release therapies for vision-threatening eye diseases.